Compare AbbVie Inc (ABBV) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Northrop Grumman Corporation — how do they compare? AbbVie Inc trades at $253.61 (market cap $449.91B), while Northrop Grumman Corporation trades at $544.31 (market cap $77.98B). The key difference: AbbVie Inc is far larger — about 5.8× Northrop Grumman Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | NOC | |
|---|---|---|
Market Cap | $449.91B | $77.98B |
Sector | Health | Industrials |
52-Week High | $261.07 | $768.02 |
52-Week Low | $184.85 | $496.02 |
Enterprise Value | $513.38B | $92.21B |
Dividend Yield | 2.72% | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Northrop Grumman (NOC) trades at $549.04, showing minimal daily movement. The stock exhibits a bullish technical trend, supported by strong fundamentals including a 10.8% net income margin and consistent earnings beats. Recent news highlights contract wins and positive defense sector sentiment. Analyst consensus is strongly bullish with a $694.40 price target, indicating significant upside potential from current levels.
The outlook remains positive given the company's $95.61B backlog and stable cash flow generation. Key risks include political budget uncertainty and execution challenges. With solid institutional support and improving profitability metrics, NOC presents a compelling opportunity for investors seeking defense sector exposure, though geopolitical developments require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
